Skip to main content

$1.51 (0%)

High

$1.54

Low

$1.51

Trades

21

Turnover

$19,629

Volume

12,937
30 June 2023 at 3:54pm
Register to track ZLD and receive email alerts.
Subject
ZLD Ann: Amendment to ASX announcement - Zelira's diabetic nerve pai

ZLD Ann: Initial Director's Interest Notice

ZLD Ann: Final Director's Interest Notice

ZLD Ann: Proposed issue of securities - ZLD

ZLD Ann: Zelira Non-Executive Director Appointed

ZLD Ann: Top Line Results Investor Presentation

ZLD Ann: Investor Webinar - Top line trial results

ZLD Ann: Zeliras diabetic nerve pain drug outperforms Lyrica

ZLD Ann: Trading Halt

ZLD Ann: ZLD secures additional US$3.25M investment in HOPE SPV

ZLD Ann: Appendix 4C Cash Flow Report

ZLD Ann: March 2023 Quarterly Activities Report

ZLD Ann: Section 708A Cleansing Notice

ZLD Ann: Application for quotation of securities - ZLD

ZLD Ann: Proposed issue of securities - ZLD

ZLD Ann: Zelira raises A$1.77 million from US-based investors

ZLD Ann: Trading Halt

ZLD Ann: Appendix 4D & FY23 Interim Financial Report

ZLD Ann: Zelira HOPE 1 SPV Investor Presentation

ZLD Ann: Initial Director's Interest Notice

ZLD Ann: Zelira HOPE 1 SPV Investor Briefing Webinar

ZLD Ann: Zelira Executive Director Appointed

ZLD Ann: Trading Halt

ZLD Ann: ZLD secures US$8.6 million funding for HOPE 1 US FDA trials

ZLD Ann: Trading Halt

ZLD Ann: Appendix 4C Cash Flow Report

ZLD Ann: December 2022 Quarterly Activities Report

ZLD Ann: Zelira receives $1.14 million cash R&D Tax Incentive

ZLD Ann: Receipt of Creso Shares and Settlement of Health House loan

ZLD Ann: Partial Receipt and variation of Health House loan

ZLD Ann: HHI: Scheme implementation deed executed

ZLD Ann: ZLD Completes Enrolment for Diabetic Nerve Pain Drug Trial

ZLD Ann: New Constitution

ZLD Ann: Results of Meeting

ZLD Ann: 2022 Annual General Meeting Presentation

ZLD Ann: Zelira Retail Investor Presentation

ZLD Ann: Sydney Retail Investor Briefing Time Change

ZLD Ann: Zelira Retail Investor Briefing Details

ZLD Ann: Appendix 4C Cash Flow Report

ZLD Ann: September 2022 Quarterly Activities Report

ZLD Ann: Notice of Annual General Meeting/Proxy Form

ZLD Ann: Letter to Shareholders

ZLD Ann: Notification of cessation of securities - ZLD

ZLD Ann: Diabetic Nerve Pain Drug Trial Summary Update

ZLD Ann: AGM Date and Closing Date for Director Nominations

ZLD Ann: Annual Report to shareholders

ZLD Ann: ZLDs Diabetic Nerve Pain Drug Trial Two-Thirds Enrolled

ZLD Ann: Partial Receipt of Health House Loan

ZLD Ann: Investor Briefing Webinar Presentation

ZLD Ann: Investor Briefing Webinar Details

Register to track ZLD and receive email alerts.

Similar Companies

CAN
CPH
EOF
IHL
MVP
MYX
NEU
PBP
RCE
SPL